Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals

Zacks 12:30 ET

Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock

Kevin Travers11:19 ET

Incyte Announced Results From Phase 3 Trial Evaluating Retifanlimab In Combination With Platinum-based Chemotherapy In Patients With Non-small Cell Lung Cancer At ESMO Congress; Said Phase 3 POD1UM-304 Trial Met Primary Endpoint Of Overall Survival...

BenzingaDec 7 15:48 ET

Express News | Incyte Corp - Phase 3 Pod1Um-304 Trial Meets Primary and Secondary Endpoints

ReutersDec 7 07:30 ET

Express News | Incyte Announces Positive Results From Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination With Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer

ReutersDec 7 07:30 ET

Weekly Buzz: Now THOSE are records!!

Kevin TraversDec 6 16:32 ET